The EWS Antibody (PAC021454) is a high-quality polyclonal antibody designed for research involving the EWS protein, which is commonly associated with Ewing sarcoma - a type of bone cancer frequently found in children and teenagers. This antibody is raised in rabbits and has been validated for use in various applications, including Western blot analysis. By specifically binding to the EWS protein, researchers can accurately detect and analyze EWS expression in different cell types.The EWS protein is a key player in the development and progression of Ewing sarcoma, making it a crucial target for cancer research.
Understanding the mechanisms and functions of EWS can provide valuable insights into the pathology of this aggressive cancer and potentially lead to the development of targeted therapeutic interventions. By utilizing the EWS Antibody in studies, researchers can further elucidate the role of EWS in cancer biology and potentially uncover new treatment strategies for Ewing sarcoma.
Antibody Name:
EWS Antibody (PACO21454)
Antibody SKU:
PACO21454
Size:
100ul
Host Species:
Rabbit
Tested Applications:
ELISA, WB
Recommended Dilutions:
ELISA:1:2000-1:10000, WB:1:500-1:1000
Species Reactivity:
Human, Mouse, Rat
Immunogen:
Peptide sequence around aa.213~217(T-Y-G-Q-P)derived from Human EWS.
Form:
Liquid
Storage Buffer:
Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Purification Method:
Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Clonality:
Polyclonal
Isotype:
IgG
Conjugate:
Non-conjugated
Western blot analysis of extracts from 293 and 3T3 cells using EWS Antibody.
Background:
This gene encodes a multifunctional protein that is involved in various cellular processes, including gene expression, cell signaling, and RNA processing and transport. The protein includes an N-terminal transcriptional activation domain and a C-terminal RNA-binding domain. Chromosomal translocations between this gene and various genes encoding transcription factors result in the production of chimeric proteins that are involved in tumorigenesis. These chimeric proteins usually consist of the N-terminal transcriptional activation domain of this protein fused to the C-terminal DNA-binding domain of the transcription factor protein. Mutations in this gene, specifically a t(11;22)(q24;q12) translocation, are known to cause Ewing sarcoma as well as neuroectodermal and various other tumors. Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 1 and 14.
